NGNE Neurogene Inc.
USHealthcareAs of 2026-07-10 16:00
Why NGNE matters now
Neurogene Inc. (NGNE) is a US stock in Healthcare. The latest InvestLog snapshot shows $39.63 with -7.49% on the session and $626.2M in market capitalization; recent performance reads 1-month +17.30% and YTD +53.06%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-30.9M, and EPS of $-1.39. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -16.6%.
The latest indexable market news headline is "Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $70.00; recent insider activity includes Woods Keith filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.96
P/S
0.00
EV/EBITDA
-4.01
DCF Value
$4.36
FCF Yield
-16.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-37.9%
ROA
-37.5%
ROIC
-44.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-30.9M | $-1.39 |
| Q4 2025 | $0.00 | $-24.7M | $-1.60 |
| FY 2025 | $0.00 | $-90.4M | $-4.24 |
| Q3 2025 | $0.00 | $-21.0M | $-0.99 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$69.67
Target (Median)
$70.00
Target Range
$69.00 - $70.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
2.04
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.